Home > Neurology > ECTRIMS 2019 > Optimising Long-Term Benefit of MS Treatment > Predicting long-term sustained disability progression

Predicting long-term sustained disability progression

Presented By
Prof. Tomas Kalincik, University of Melbourne, Australia
The ultimate treatment goal in MS is to prevent disability over the long term. However, randomised clinical trials (RCTs) usually evaluate short-term effect of therapies on disability, in the form of confirmed disability progression (CDP) after 3 and 6 months. Additionally, CDP events overestimate the accumulation of irreversible disability by up to 30% [1]. Changes in bowel and bladder function, and in pyramidal, cerebellar, and cerebral domains contribute more to confirmed EDSS worsening than other neurological domains [2]. Using the global MSBase registry, Prof. Tomas Kalincik (University of Melbourne, Australia), studied 6-month CDP events as indicators of long-term disability worsening. A total of 11,435 CDP events were identified in 6,902 patients. This study showed that CDP can be defined in more detail at the occurrence of a CDP event. A low probability of recovery from a CDP event is associated with several factors, such as older age, male ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on